Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction

R. Latagliata Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

M. Breccia Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

A. Pulsoni Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

M. A. Aloe Spiriti Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

G. M. D'elia Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

A. Spadea Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

E. Montefusco Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

G. Luzi Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

P. Betró Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

M. C. Petti Dipartimento di Biotecnologie Cellulari ed Ematologia, Università “La Sapienui” of Rome, Via Benevento 6, 00161, Rome, Italy

show all

Abstract

To evaluate the addition of a third drug to standard induction chemotherapy in patients with MDS-AML, 23 patients (males/ females 13/10, median age 54.3 years, range 24 - 74 years, median MDS duration 9.8 months, range 2-39 months) who received a standard 2-drugs induction were compared with 23 patients (males/females 11/12, median age 45.6 months, range 21-60 years, median MDS duration 8.3 months, range 2-29 months) who received an intensified 3-drugs induction with etoposide. CR rate, median CR duration and median OS were similar in both groups (48% vs 56%, 4.8 vs 5.9 months, 6.5 vs 7.0 months respectively). Among responding patients, all but one, who underwent allogeneic bone marrow transplantation, relapsed. In conclusion, addition of a third drug (etoposide) does not seem to significantly improve the poor prognosis of MDS-AML patients.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction

Information for

Open access

Opportunities

Help and information

Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature